[
  {
    "ts": null,
    "headline": "I'm Still Bullish On Tempus AI",
    "summary": "TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEMâs main bet is now on AI for healthcare applications. Read more on TEM.",
    "url": "https://finnhub.io/api/news?id=a2e65b01bfc739ca86e2b1b57410e3a58b37d86e2633893b74f2250556027045",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749290769,
      "headline": "I'm Still Bullish On Tempus AI",
      "id": 135106296,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/640351075/image_640351075.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEMâs main bet is now on AI for healthcare applications. Read more on TEM.",
      "url": "https://finnhub.io/api/news?id=a2e65b01bfc739ca86e2b1b57410e3a58b37d86e2633893b74f2250556027045"
    }
  },
  {
    "ts": null,
    "headline": "Patents and economies of scale support Pfizer's wide moat",
    "summary": "Patent-protected drugs provide strong pricing power, enabling returns on invested capital.",
    "url": "https://finnhub.io/api/news?id=bf2ab20e1f8bb746a5404b0bee9aa327107723fa433627a9314630c2ba21a731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749290378,
      "headline": "Patents and economies of scale support Pfizer's wide moat",
      "id": 135105910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Patent-protected drugs provide strong pricing power, enabling returns on invested capital.",
      "url": "https://finnhub.io/api/news?id=bf2ab20e1f8bb746a5404b0bee9aa327107723fa433627a9314630c2ba21a731"
    }
  }
]